Exclusive Summary

• Innovative Modality & Target: UB692 is a potential First-in-Class inhaled siRNA targeting MMP7, delivering treatment directly to the lungs to significantly minimize systemic toxicity.
• Exceptional Patient Compliance: Backed by robust Non-Human Primate (NHP) data, UB692 demonstrates a long-acting pharmacokinetic profile that supports a bimonthly (Q2M) nebulization dosing schedule, fundamentally resolving the poor compliance associated with current daily oral therapies.
• Tremendous Monotherapy & Combo Potential: Preclinical models show monotherapy efficacy comparable or superior to the current Standard of Care (SoC), and striking synergistic efficacy when combined with blockbusters like Pirfenidone, Nintedanib, making it highly attractive for MNCs looking for pipeline expansion.

Asset Materials

Contact Us for Full Materials